Aged ; Anti-Bacterial Agents ; therapeutic use ; Humans ; Levofloxacin ; Middle Aged ; Ofloxacin ; therapeutic use ; Pneumoconiosis ; complications ; Tuberculosis, Pulmonary ; complications ; drug therapy

OBJECTIVETo study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis.

METHODSEighty patients with Type IIIA prostatitis were equally randomized into a Longqingpian group and a Puleanpian group, both treated for 12 weeks. The former were given Longqingpian (once 6 tablets, twice a day) combined with Levofloxacin (once 0.2 g, twice a day) during the first 4 weeks, followed by Longqingpian alone (once 6 tablets, twice a day) for 8 weeks. The latter received Puleanpian (once 4 tablets, 3 times a day) combined with Levofloxacin (once 0.2 g, twice a day) in the initial 4 weeks, followed by Puleanpian alone (once 4 tablets, 3 times a day) for 8 weeks. Before and 4, 8, and 12 weeks after the treatment, all the patients were evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and EPS examination.

RESULTSAfter 4-week, 8-week and 12-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life dropped significantly in both groups compared with pre-treatment (P < 0.05 or 0.01), so did the leukocyte count in EPS (P < 0.05). Compared with the 4-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life were shown to be significantly different (P < 0.05) in the Longqingpian group from the 8-week and 12-week treatment, except the leukocyte count in EPS. However, there was no significant difference between the 8-week and 12-week treatment in any of the indexes (P > 0.05). Longqingpian effected significant differences in the above indexes (P < 0.05), while Puleanpian did not after the treatment (P > 0.05). And the lecithin Amato body analysis revealed no significant changes in EPS after the treatment in either group (P > 0.05).

CONCLUSIONLongqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients.

Adult ; Chronic Disease ; Humans ; Levofloxacin ; Male ; Middle Aged ; Ofloxacin ; therapeutic use ; Phytotherapy ; Prostatitis ; drug therapy

Anti-Bacterial Agents ; therapeutic use ; Antitubercular Agents ; therapeutic use ; Coal Mining ; Drug Therapy, Combination ; Follow-Up Studies ; Humans ; Male ; Ofloxacin ; therapeutic use ; Pneumoconiosis ; complications ; Silicotuberculosis ; drug therapy

OBJECTIVETo evaluate the efficacy and safety of corticoid in combination with an antibiotic in the treatment of chronic nonbacterial prostatitis (CNP).

METHODSWe used the randomized, double-blind and parallel contrasted method, selected 160 CNP patients via the Stamey test, EPS examination and NIH-CPSI scores, and equally randomized them into an experimental group (with 1 case missing) and a control group. The former received prednisone and levofloxacin for 2 weeks followed by another 2-week administration of levofloxacin only, while the latter were given levofloxacin and placebo in the first 2 weeks and placebo only in the next 2. All the patients were evaluated by NIH-CPSI scores and EPS results and followed up for adverse events after 2 and 4 weeks of treatment.

RESULTSThe total NIH-CPSI score, the pain index, voiding index and quality of life (QOL) score in the experimental group were decreased by 9.56 +/- 2.05, 4.59 +/- 1.18, 2.38 +/- 1.24 and 2.59 +/- 2 1.20 after the 2-week treatment, and 11.72 +/- 2.41, 5.51 +/- 1.42, 2.92 +/- 1.17 and 3.33 +/- 1.08 after the 4-week treatment; while those in the control group were reduced by 6.53 +/- 2.70, 3.20 +/- 1.30, 1.40 +/- 1.05 and 1.80 +/- 1.15 after the 2-week treatment, and 8.53 -/+ 2.91, 3.88 +/- 1.44, 2.08 +/- 1.11 and 2.55 +/- 1.33 after the 4-week treatment, with significant differences between the two groups as well as between pre- and post-treatment (P < 0.01), but not between the 2- and 4-week treatment (P > 0.05). Statistically significant differences were also observed in the count of WBCs in EPS between not only pre- and post-treatment, but also the 2- and 4-week treatment (P < 0.01). No serious adverse events were recorded, nor were significant differences in the tolerance to corticoid and placebo.

CONCLUSIONPrednisone in combination with an antibiotic can effectively relieve pain and voiding symptoms, improve QOL and reduce WBC in the EPS of CNP patients, and therefore well deserves to be recommended in clinical application. But its long-term efficacy and tolerance are yet to be further studied.

Adolescent ; Adrenal Cortex Hormones ; therapeutic use ; Adult ; Anti-Bacterial Agents ; therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Glucocorticoids ; therapeutic use ; Humans ; Levofloxacin ; Male ; Middle Aged ; Ofloxacin ; therapeutic use ; Prednisone ; therapeutic use ; Prostatitis ; drug therapy ; Treatment Outcome ; Young Adult

Fitz-Hugh-Curtis syndrome has been described as focal perihepatitis accompanying pelvic inflammatory disease caused by Neisseria gonorrhea and Chlamydia trachomatis. The highest incidence occurs in young, sexually active females. However, the syndrome has been reported to occur infrequently in males, according to the foreign literature. The predominant symptoms are right upper quadrant pain and tenderness, and pleuritic right sided chest pain. The clinical presentation is similar in men and women. In women, the spread of infection to liver capsule is thought to occur directly from infected fallopian tube via the right paracolic gutter. In men, hematogenous and lymphatic spread is thought to be postulated. Recently, we experienced a case of Fitz-Hugh-Curtis syndrome occurred in a man. As far as we know, it is the first report in Korea, and we report a case with a review of the literature.
Adult ; Anti-Bacterial Agents/therapeutic use ; Humans ; Male ; Mycoplasma Infections/*diagnosis/drug therapy ; *Mycoplasma genitalium ; Ofloxacin/therapeutic use ; Pelvic Infection/*diagnosis/drug therapy ; Tomography, X-Ray Computed

Anti-Bacterial Agents ; adverse effects ; Humans ; Immunoglobulins, Intravenous ; therapeutic use ; Immunologic Factors ; therapeutic use ; Levofloxacin ; Ofloxacin ; adverse effects ; Stevens-Johnson Syndrome ; drug therapy ; etiology

Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and nontyphoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.
Anti-Infective Agents/*therapeutic use ; *Aza Compounds ; Bacteria/*drug effects ; Ciprofloxacin/therapeutic use ; *Fluoroquinolones ; Haemophilus influenzae/drug effects ; Korea ; Microbial Sensitivity Tests ; Moraxella/drug effects ; Naphthyridines/*therapeutic use ; Ofloxacin/therapeutic use ; *Quinolines ; Streptococcus pneumoniae/drug effects

OBJECTIVETo evaluate the efficacy of Integrative Chinese and western medicine (ICWM) in treating SARS.

METHODSBy controlled paralled design, 49 patients of SARS were studied, they were divided into the control group (n = 29) and the ICWM group (n = 20). The former was treated according to the "Recommended Program for Treatment of SARS" provided by Health Ministry, by administering of such drugs as Ribavirin, Levofloxacin, Thymopentin, Azithromycin, etc, the latter was treated with the ICWM protocol for SARS of "Special Technological Action to Prevent and Treat SARS" provided by Science and Technology Ministry.

RESULTS(1) The time for improving symptom in the ICWM group was 5.10 days and that in the control group was 7.62 days, the difference between them was significant (P < 0.05); (2) The days and amount for use hormone before subtract in the two group were similar, with insignificant difference (P > 0.05); (3) The days and amount for use hormone after subtract in the two groups were significantly different (P < 0.05); (4) The time for improving peripheral WBC count and absolute value of lymphocyte, as well as for absorption time of shadow in chest film were not different significantly between the two groups (P > 0.05).

CONCLUSIONIn treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course.

Adolescent ; Adult ; Aged ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Levofloxacin ; Male ; Methylprednisolone ; therapeutic use ; Middle Aged ; Ofloxacin ; therapeutic use ; Phytotherapy ; Ribavirin ; therapeutic use ; Severe Acute Respiratory Syndrome ; drug therapy ; immunology

Acute phlegmonous gastritis is an uncommon disease, often fatal condition characterized by suppurative bacterial infection of the gastric wall. It has a high mortality rate mainly because the diagnosis is usually made late. Until recently, gastrectomy in combination with antibiotics was recommended. We had experienced a case of 66-year-old man presented with epigastric pain, nausea, vomiting, and hematemesis, followed by aspiration pneumonia. At upper gastrointestinal endoscopy, the gastric lumen was narrow, and the mucosa was severely inflamed, which was erythematous, swelled, and showed necrotic areas covered with purulent exudate. Klebsiella oxytoca and Acinetobacter lwoffii were isolated in the gastric tissue culture. Contrast-enhanced computerized tomography scan of abdomen demonstrated diffuse gastric wall thickening and an intramural abscess in the gastric antral wall. Although delayed gastric emptying by gastroparesis prolonged the in-hospital period, the only medical treatment with antibiotics alone successfully cured the patient without gastrectomy.
Acinetobacter/isolation & purification ; Acute Disease ; Aged ; Anti-Bacterial Agents/*therapeutic use ; Anti-Infective Agents/therapeutic use ; Cefotaxime/therapeutic use ; Ceftriaxone/therapeutic use ; Ciprofloxacin/therapeutic use ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination ; Gastritis/*diagnosis/drug therapy/microbiology ; Gastroparesis/*diagnosis/microbiology ; Gastroscopy ; Humans ; Imipenem/therapeutic use ; Klebsiella oxytoca/isolation & purification ; Male ; Ofloxacin/therapeutic use ; Pneumonia/diagnosis/drug therapy ; Tomography, X-Ray Computed

OBJECTIVETo evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis.

METHODSA total of 180 patients with type III A prostatitis were equally randomized into a treatment group, which received Yiqigushen Capsule combined with levofloxacin, and a control group, which was given Yiqigushen Capsule only, both for 4 weeks. NIH-CPSI scores and leukocyte counts in the expressed prostatic secretions of all the patients were analyzed before and after the treatment.

RESULTSAfter the treatment, NIH-CPSI scores and leukocyte counts in the expressed prostatic secretions of both the groups were significantly decreased compared with pre-treatment (P < 0.05 or 0.01), with statistic differences in NIH-CPSI scores but not in leukocyte counts (P < 0.05) between the two groups.

CONCLUSIONYiqigushen Capsule combined with levofloxacin is highly effective for type III A prostatitis.

Adult ; Anti-Infective Agents, Urinary ; therapeutic use ; Capsules ; Chronic Disease ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Levofloxacin ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Ofloxacin ; therapeutic use ; Prostatitis ; drug therapy ; pathology ; Treatment Outcome